Conference Coverage

VIDEO: BeST: Does a treat-to-target approach reduce RA mortality?


 

AT ACR 2014

References

BOSTON - With follow up every 3 months, the survival rates of RA patients were comparable to those of the general population in a 10-year study of patients in the Netherlands. Dr. Iris Markusse of Leiden University Medical Center credits regimens that were tailored to keep the Disease Activity Score at levels of 2.4 or lower. Further, the medications used in this strategy did not increase patient mortality. Dr. Markusse discusses the findings of BeST in an exclusive interview at the annual meeting of the American College of Rheumatology.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Disease activity, not lipid levels, appear to affect CV risk with tocilizumab
MDedge Rheumatology
Current use of COX-2 inhibitors linked to increased mortality after ischemic stroke
MDedge Rheumatology
Eastern United States has the highest arthritis rates
MDedge Rheumatology
Control of early RA maintained with reduced-dose etanercept plus methotrexate
MDedge Rheumatology
Abatacept + methotrexate makes early drug-free RA remission possible
MDedge Rheumatology
Chronic inflammatory disease patients at greater risk of major CV events
MDedge Rheumatology
Children born to mothers with RA more likely to be born early
MDedge Rheumatology
Veterans more likely to have arthritis at any age
MDedge Rheumatology
Evidence builds for importance of CVD, new drug targets at ACR
MDedge Rheumatology
VIDEO: RA linked to increased mortality in Nurses’ Health Study
MDedge Rheumatology